Base de dados : MEDLINE
Pesquisa : D02.886.590.263.050 [Categoria DeCS]
Referências encontradas : 31 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 31 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26408342
[Au] Autor:Serrano DR; O'Connell P; Paluch KJ; Walsh D; Healy AM
[Ad] Endereço:School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.
[Ti] Título:Cocrystal habit engineering to improve drug dissolution and alter derived powder properties.
[So] Source:J Pharm Pharmacol;68(5):665-77, 2016 May.
[Is] ISSN:2042-7158
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Cocrystallization of sulfadimidine (SDM) with suitable coformers, such as 4-aminosalicylic acid (4-ASA), combined with changes in the crystal habit can favourably alter its physicochemical properties. The aim of this work was to engineer SDM : 4-ASA cocrystals with different habits to investigate the effect on dissolution, and the derived powder properties of flow and compaction. METHODS: Cocrystals were prepared in a 1 : 1 molar ratio by solvent evaporation using ethanol (habit I) or acetone (habit II), solvent evaporation followed by grinding (habit III) and spray drying (habit IV). KEY FINDINGS: Powder X-ray diffraction showed Bragg peak position was the same in all the solid products. The peak intensity varied, indicating different preferred crystal orientation confirmed by SEM micrographs: large prismatic crystals (habit I), large plate-like crystals (habit II), small cube-like crystals (habit III) and microspheres (habit IV). The habit III exhibited the fasted dissolution rate; however, it underwent a polymorphic transition during dissolution. Habits I and IV exhibited the highest Carr's compressibility index, indicating poor flowability. However, habits II and III demonstrated improved flow. Spray drying resulted in cocrystals with improved compaction properties. CONCLUSIONS: Even for cocrystals with poor pharmaceutical characteristics, a habit can be engineered to alter the dissolution, flowability and compaction behaviour.
[Mh] Termos MeSH primário: Acedapsona/química
Ácido Aminossalicílico/química
Anti-Infecciosos/química
[Mh] Termos MeSH secundário: Acetona/química
Aerossóis
Cristalização
Cristalografia por Raios X
Combinação de Medicamentos
Composição de Medicamentos
Etanol/química
Cinética
Microscopia Eletrônica de Varredura
Modelos Químicos
Modelos Moleculares
Difração de Pó
Pós
Solubilidade
Solventes/química
Propriedades de Superfície
Tecnologia Farmacêutica/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Anti-Infective Agents); 0 (Drug Combinations); 0 (Powders); 0 (Solvents); 0GZ72U84TN (Acedapsone); 1364PS73AF (Acetone); 3K9958V90M (Ethanol); 5B2658E0N2 (Aminosalicylic Acid)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170515
[Lr] Data última revisão:
170515
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150927
[St] Status:MEDLINE
[do] DOI:10.1111/jphp.12476


  2 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15217321
[Au] Autor:Norman G; Joseph G; Richard J
[Ad] Endereço:Department of Community Health, Schieffelin Leprosy Research and Training Center, Karigiri, Vellore, India. Karigiri@vsnl.com
[Ti] Título:Relapses in multibacillary patients treated with multi-drug therapy until smear negativity: findings after twenty years.
[So] Source:Int J Lepr Other Mycobact Dis;72(1):1-7, 2004 Mar.
[Is] ISSN:0148-916X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Schieffelin Leprosy Research and Training Center at Karigiri, India participated in several of the World Health Organization (WHO) trials. The first trial on combined therapy in multi-bacillary leprosy was initiated in 1981. The main objectives of this field trial were to evaluate the efficacy of WHO recommended regimens in preventing relapses, especially drug resistance relapses. This paper reports on the relapses twenty years after patients were inducted into the WHO field trial. Between 1981 and 1982, 1067 borderline lepromatous and lepromatous patients were inducted into the WHO field trial for combined therapy in multi-bacillary leprosy trial. Among them, 357 patients were skin smear positive. During the follow-up in 2002, only 173 of them could be traced and assessed. The mean duration of follow-up was 16.4 +/- 1.83 years. Two patients relapsed 14 and 15 years after being released from treatment, the relapse rate being 0.07 per 100 person years follow-up. Drug susceptibility tests done on one of the relapsed patients revealed drug sensitive organisms to all multi-drug therapy drugs.
[Mh] Termos MeSH primário: Hansenostáticos/uso terapêutico
Hanseníase Virchowiana/prevenção & controle
Mycobacterium leprae/efeitos dos fármacos
[Mh] Termos MeSH secundário: Acedapsona/farmacologia
Acedapsona/uso terapêutico
Idoso
Clofazimina/farmacologia
Clofazimina/uso terapêutico
Dapsona/farmacologia
Dapsona/uso terapêutico
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Índia
Hansenostáticos/farmacologia
Hanseníase Virchowiana/tratamento farmacológico
Hanseníase Virchowiana/microbiologia
Masculino
Testes de Sensibilidade Microbiana
Recidiva
Rifampina/farmacologia
Rifampina/uso terapêutico
Organização Mundial da Saúde
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Leprostatic Agents); 0GZ72U84TN (Acedapsone); 8W5C518302 (Dapsone); D959AE5USF (Clofazimine); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:0407
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040626
[St] Status:MEDLINE


  3 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15191833
[Au] Autor:Simman R
[Ti] Título:Letter to the Editor: Management of aplasia cutis congenita in a non-scalp location.
[So] Source:Br J Plast Surg;57(5):469-70; author reply 470-2, 2004 Jul.
[Is] ISSN:0007-1226
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Bandagens
Displasia Ectodérmica/terapia
[Mh] Termos MeSH secundário: Acedapsona
Anti-Infecciosos
Cicatriz
Contraindicações
Seres Humanos
Transplante de Pele
Coxa da Perna
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0GZ72U84TN (Acedapsone)
[Em] Mês de entrada:0408
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040612
[St] Status:MEDLINE


  4 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12862255
[Au] Autor:Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
[Ad] Endereço:Schieffelin Leprosy Research & Training Centre, Karigiri, India. timokathara@satyam.net.in
[Ti] Título:Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
[So] Source:Lepr Rev;74(2):141-7, 2003 Jun.
[Is] ISSN:0305-7518
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The World Health Organization (WHO) Field Trials of multidrug therapy (MDT) started at Schieffelin Leprosy Research and Training Centre (SLR & IC), Karigiri, India in December 1981. The patients were treated with two MDT regimens. The first (regimen A) consisted of 600mg rifampicin and 300mg of clofazimine given under supervision on 2 consecutive days monthly, 225mg injection of acedapsone bimonthly and dapsone 100mg daily. The second regimen (regimen B) was the conventional MDT (WHO/MDT), rifampicin 600mg and clofazimine 300mg supervised once a month, dapsone 100mg and clofazimine 50mg daily, unsupervised. Both the regimens were administered for a minimum period of 2 years or until skin smear negativity, whichever occurred later. Thirty-four newly detected previously untreated MB patients, 16 of whom received regimen A and 18 regimen B, were reassessed. Both regimens were well accepted and well tolerated by the patients. Clofazimine discolouration was the only adverse effect of MDT seen in these patients. After completion of treatment with MDT, the patients were followed up for a total duration of 466 person-years with a mean of 13.7 +/- 1.4 years per patient. No relapse was seen.
[Mh] Termos MeSH primário: Hansenostáticos/uso terapêutico
Hanseníase/tratamento farmacológico
Pele/microbiologia
[Mh] Termos MeSH secundário: Acedapsona/administração & dosagem
Acedapsona/uso terapêutico
Adulto
Clofazimina/administração & dosagem
Clofazimina/uso terapêutico
Dapsona/administração & dosagem
Dapsona/uso terapêutico
Esquema de Medicação
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Hansenostáticos/administração & dosagem
Masculino
Rifampina/administração & dosagem
Rifampina/uso terapêutico
Resultado do Tratamento
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Leprostatic Agents); 0GZ72U84TN (Acedapsone); 8W5C518302 (Dapsone); D959AE5USF (Clofazimine); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:0307
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:030717
[St] Status:MEDLINE


  5 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11277865
[Au] Autor:Nimbalkar D; Birudaraj R; Jones PR; Smith TJ
[Ad] Endereço:Department of Physiology and Pharmacology, University of the Pacific, Stockton, CA 95211, USA.
[Ti] Título:Activation of diacetyldapsone and a preliminary evaluation of a cyclodextrin-diacetyldapsone complex in cultured lung cells.
[So] Source:Biotechnol Appl Biochem;33(Pt 2):123-5, 2001 Apr.
[Is] ISSN:0885-4513
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A diacetyldapsone-2-hydroxypropyl-beta-cyclodextrin complex (DADDS-CD) was evaluated with regard to the ability of cultured lung cells to activate DADDS to the active metabolite dapsone. The same system was used to assess the effect of the complex on cell growth. The complex was incubated with cells for periods of 24 to 72 h, followed by extraction of metabolites from the incubation medium and analysis by HPLC. In addition, the Trypan Blue exclusion technique was used to assess cell viability during this time period. Results indicated that lung cells could activate DADDS to dapsone and that, while the complex appeared to delay cell growth in the first 24 h period, no significant difference was seen between cells incubated in the presence and absence of the complex at 72 h. These results indicate that DADDS-CD has significant potential as a drug-delivery system for DADDS in the lung based upon the ability of the cells to activate DADDS. The mixed effects of the complex on cell growth may have important implications when considering the frequency of administration of the complex to the lung.
[Mh] Termos MeSH primário: Acedapsona/metabolismo
Ciclodextrinas/metabolismo
Pulmão/metabolismo
beta-Ciclodextrinas
[Mh] Termos MeSH secundário: Acedapsona/toxicidade
Anti-Infecciosos/metabolismo
Anti-Infecciosos/toxicidade
Técnicas de Cultura de Células/métodos
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Ciclodextrinas/toxicidade
Ativação Enzimática/efeitos dos fármacos
Inibidores do Crescimento/metabolismo
Inibidores do Crescimento/toxicidade
Seres Humanos
Hidrólise
Pulmão/citologia
Pulmão/efeitos dos fármacos
Pulmão/enzimologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Cyclodextrins); 0 (Growth Inhibitors); 0 (beta-Cyclodextrins); 0GZ72U84TN (Acedapsone); 98513-20-3 (2-hydroxyethyl-beta-cyclodextrin)
[Em] Mês de entrada:0108
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010330
[St] Status:MEDLINE


  6 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11221089
[Au] Autor:Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
[Ad] Endereço:Department of Community Health, Schieffelin Leprosy Research and Training Center, Karigiri, Vellore District, Tamil Nadu, South India 632 106.
[Ti] Título:Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
[So] Source:Int J Lepr Other Mycobact Dis;68(3):272-6, 2000 Sep.
[Is] ISSN:0148-916X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The histoid type of leprosy has been described as occurring in lepromatous leprosy patients who relapse after many years of apparently successful dapsone monotherapy. Three patients who had received the World Health Organization-recommended regimens of multidrug therapy (WHO/MDT) relapsed as histoid leprosy 12-15 years after completion of treatment. In one patient, through mouse foot pad studies, the bacilli were found to be sensitive to rifampin and clofazimine and resistant to dapsone. In the other two patients mouse foot pad studies were inconclusive. The patients were re-started on WHO/MDT. Two patients took regular treatment and improved, both clinically and bacteriologically. One patient was irregular in treatment, and 1 year after re-starting WHO/MDT nodules were still present although the bacterial index had fallen slightly.
[Mh] Termos MeSH primário: Acedapsona/uso terapêutico
Clofazimina/uso terapêutico
Dapsona/uso terapêutico
Hansenostáticos/uso terapêutico
Hanseníase Virchowiana/patologia
Rifampina/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Animais
Criança
Clofazimina/administração & dosagem
Dapsona/administração & dosagem
Resistência Microbiana a Medicamentos
Quimioterapia Combinada
Feminino
Seres Humanos
Índia
Hansenostáticos/administração & dosagem
Hanseníase Virchowiana/tratamento farmacológico
Masculino
Camundongos
Camundongos Endogâmicos CBA
Mycobacterium leprae/efeitos dos fármacos
Recidiva
Rifampina/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Leprostatic Agents); 0GZ72U84TN (Acedapsone); 8W5C518302 (Dapsone); D959AE5USF (Clofazimine); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:0103
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010228
[St] Status:MEDLINE


  7 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11023757
[Au] Autor:Smith CM; Smith WC
[Ad] Endereço:Department of Public Health, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, U.K.
[Ti] Título:Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MILEP2 Study Group. Mucosal Immunology of Leprosy.
[So] Source:J Infect;41(2):137-42, 2000 Sep.
[Is] ISSN:0163-4453
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To quantify the efficacy of chemoprophylaxis against leprosy. METHOD: Literature searching of Medline and Embase databases, hand-searching of references and correspondence with investigators. STUDY SELECTION: published papers relating to the prevention of leprosy and the use of chemotherapy in leprosy were identified for critical appraisal. Trials were selected and grouped into three categories according to study design and control groups. DATA ANALYSIS: the relative risks (RR) with 95% confidence intervals were calculated from the original data using a random effects model. To assess the cost-effectiveness of chemoprophylaxis, a further analysis of the rates of disease in the trial and control groups was done based on the numbers needed to be treated (NNT) to prevent one new case of leprosy. RESULTS: A total of 14 trials were identified from 127 published papers on chemoprophylaxis of leprosy. The trials were categorized into randomized controlled trials, non-randomized controlled trials, and uncontrolled trials. The overall results of the meta-analysis shows that chemoprophylaxis gives around 60% protection against leprosy. The NNT are low in trials of household contacts. CONCLUSIONS: The evidence shows that chemoprophylaxis against leprosy is an effective way to reduce the incidence of leprosy, particularly in household contacts. The role of chemoprophylaxis needs to be re-examined using newer drugs given the continuing case detection rates globally.
[Mh] Termos MeSH primário: Hansenostáticos/uso terapêutico
Hanseníase/prevenção & controle
[Mh] Termos MeSH secundário: Acedapsona/uso terapêutico
Ensaios Clínicos como Assunto
Análise Custo-Benefício
Dapsona/uso terapêutico
Seres Humanos
Hansenostáticos/economia
Hanseníase/epidemiologia
Rifampina/uso terapêutico
Fatores de Risco
Topografia Médica
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Leprostatic Agents); 0GZ72U84TN (Acedapsone); 8W5C518302 (Dapsone); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:0101
[Cu] Atualização por classe:140728
[Lr] Data última revisão:
140728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:001012
[St] Status:MEDLINE


  8 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10700928
[Au] Autor:Blanc LJ
[Ad] Endereço:Western Pacific Regional Office, World Health Organization, Manila, The Philippines.
[Ti] Título:Trials of preventive therapy.
[So] Source:Int J Lepr Other Mycobact Dis;67(4 Suppl):S7-9, 1999 Dec.
[Is] ISSN:0148-916X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Acedapsona/uso terapêutico
Dapsona/uso terapêutico
Hansenostáticos/uso terapêutico
Hanseníase/prevenção & controle
Rifampina/uso terapêutico
[Mh] Termos MeSH secundário: Quimioprevenção
Ensaios Clínicos como Assunto
Seres Humanos
Índia/epidemiologia
Hanseníase/epidemiologia
Ilhas do Pacífico/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Leprostatic Agents); 0GZ72U84TN (Acedapsone); 8W5C518302 (Dapsone); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:0003
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000304
[St] Status:MEDLINE


  9 / 31 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8794991
[Au] Autor:Coleman MD; Pahal KK; Gardiner JM
[Ad] Endereço:Department of Pharmaceutical Sciences, Aston University, Birmingham, UK.
[Ti] Título:The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in-vitro.
[So] Source:J Pharm Pharmacol;48(4):401-6, 1996 Apr.
[Is] ISSN:0022-3573
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The fates of both dapsone and monoacetyl hydroxylamine have been studied in terms of acetylation and deacetylation within the human erythrocyte in-vitro. A comparison between the two metabolites showed equipotency in methaemoglobin generation at 15 min, although the monoacetyl derivative was the more rapid haemoglobin oxidizer. Within the erythrocytes, both dapsone and monoacetyl hydroxylamines were found to undergo acetylation, deacetylation and diacetylation. Of the inhibitors of acetylation studied, folate caused an increase in methaemoglobin formation associated with both metabolites, which led to a rise in both acetylated and non-acetylated amine formation. Amethopterin was associated with a rise in hydroxylamine mediated methaemoglobin formation which coincided with a fall in acetylated products. It is possible that the hydroxylamines undergo erythrocytic processes of acetylation and deacetylation before methaemoglobin-mediated reduction to their respective amines.
[Mh] Termos MeSH primário: Aminas/farmacocinética
Anti-Infecciosos/farmacocinética
Dapsona/farmacocinética
Eritrócitos/metabolismo
[Mh] Termos MeSH secundário: Acedapsona/sangue
Acetilação
Adulto
Aminas/sangue
Anti-Infecciosos/sangue
Cromatografia Líquida de Alta Pressão
Dapsona/sangue
Remoção de Radical Alquila
Ácido Fólico/farmacologia
Antagonistas do Ácido Fólico/farmacologia
Glucose/farmacologia
Hematínicos/farmacologia
Seres Humanos
Técnicas In Vitro
Metemoglobina/metabolismo
Metotrexato/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amines); 0 (Anti-Infective Agents); 0 (Folic Acid Antagonists); 0 (Hematinics); 0GZ72U84TN (Acedapsone); 8W5C518302 (Dapsone); 9008-37-1 (Methemoglobin); 935E97BOY8 (Folic Acid); IY9XDZ35W2 (Glucose); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:9612
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:960401
[St] Status:MEDLINE


  10 / 31 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:2486227
[Au] Autor:Olivares Sabournin R; González Segredo AB
[Ti] Título:[Bacteriologic study in patients with multibacillary leprosy treated with rifampicin and acedapsone].
[Ti] Título:Estudio bacteriológico en pacientes con lepra multibacilar tratados con rifampicina y acedapsone..
[So] Source:Rev Cubana Med Trop;41(2):307-12, 1989 May-Aug.
[Is] ISSN:0375-0760
[Cp] País de publicação:Cuba
[La] Idioma:spa
[Ab] Resumo:A bacteriologic study of 116 patients with multibacillary leprosy from Guantanamo City is made. Samples for bacteriologic examination were derived from both auricular lobules, the two elbows, and the middle phalanges of the third finger. The microscopic examination found acid-alcohol-resistant bacilli in 19% of patients, while failure to find any of these organisms occurred in 81%.
[Mh] Termos MeSH primário: Acedapsona/uso terapêutico
Hanseníase/tratamento farmacológico
Hanseníase/microbiologia
Rifampina/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
Fatores de Tempo
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0GZ72U84TN (Acedapsone); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:9101
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:890501
[St] Status:MEDLINE



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde